Australia markets open in 7 hours 3 minutes

Vertex Pharmaceuticals Incorporated (0QZU.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
476.05-5.95 (-1.23%)
At close: 05:39PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.41
52-week change 337.54%
S&P500 52-week change 322.93%
52-week high 3480.99
52-week low 3290.87
50-day moving average 3424.38
200-day moving average 3373.25

Share statistics

Avg vol (3-month) 32.91k
Avg vol (10-day) 31.2k
Shares outstanding 5255.56M
Implied shares outstanding 6N/A
Float 8257.27M
% held by insiders 10.10%
% held by institutions 195.79%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 39.46%
Operating margin (ttm)45.20%

Management effectiveness

Return on assets (ttm)12.82%
Return on equity (ttm)24.38%

Income statement

Revenue (ttm)10.18B
Revenue per share (ttm)39.49
Quarterly revenue growth (yoy)13.30%
Gross profit (ttm)N/A
EBITDA 4.58B
Net income avi to common (ttm)4.02B
Diluted EPS (ttm)9.48
Quarterly earnings growth (yoy)57.10%

Balance sheet

Total cash (mrq)10.17B
Total cash per share (mrq)39.42
Total debt (mrq)721.3M
Total debt/equity (mrq)3.89%
Current ratio (mrq)3.50
Book value per share (mrq)71.80

Cash flow statement

Operating cash flow (ttm)3.94B
Levered free cash flow (ttm)3.31B